U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid 
OpenAI Hires OpenClaw Creator Peter Steinberger to Advance Next-Generation AI Agents 
Anthropic’s Claude AI Reportedly Used in U.S. Operation to Capture Nicolas Maduro 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Vietnam Approves SpaceX Starlink Satellite Internet Service Amid U.S. Trade Talks 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase 
Disney Issues Cease-and-Desist to ByteDance Over Alleged AI Copyright Infringement 
Anduril Industries Seeks $8 Billion Funding at $60 Billion Valuation 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Bain Capital Secures RBI Approval to Acquire Up to 41.7% Stake in Manappuram Finance 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
RANCHO CORDOVA, Calif., April 25, 2018 -- Cesca Therapeutics Inc. (“Cesca” or the “Company”) (NASDAQ:KOOL) today announced that the Company will be exhibiting its full suite of cellular processing solutions, including CAR-TXpress™ for the semi-automated manufacture of CAR-T cell therapies, X-BACS™ for cell isolation and other X-Series™ kits, at the following cell therapy conferences in May:
- International Society of Cellular Therapy 2018 Annual Meeting
May 2 – 5, 2018
Booth: 322
Palais des congrès de Montréal
1001, Place Jean-Paul-Riopelle
Montreal, Canada
For more information: www.isct2018.com
- American Society of Gene and Cell Therapy 2018 Annual Meeting
May 16 – 19, 2018
Booth: 417
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
For more information: www.asgct.org/meetings-workshops/annual-meeting
- Phacilitate Automation Special Interest Group 2018
May 30 – 31, 2018
The Grove
Chandler’s Cross,
Watford WD3 4TG, Hertfordshire
London, UK
For more information: www.phacilitateautomation.com
About Cesca Therapeutics Inc.
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress™ platform that addresses the critical unmet need for better cellular manufacturing and controls for the emerging CAR-T immunotherapy market. Cesca is an affiliated company of China-based Boyalife Group.
Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
[email protected]
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
[email protected]
